Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiu, Bonnia-
dc.contributor.authorMa, Ronald-
dc.contributor.authorShum, Evonne-
dc.contributor.authorHormiz, Maria-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorPoon, Aurora M T-
dc.contributor.authorScott, Andrew M-
dc.identifier.citationEuropean Journal of Nuclear Medicine and Molecular Imaging 2023-12-07en_US
dc.description.abstractOur study aims to explore the current utilisation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the diagnostic pathway of pyrexia of unknown origin (PUO) and associated cost of illness in a large tertiary teaching hospital in Australia. 1257 febrile patients between June 2016 and September 2022 were retrospectively reviewed. There were 57 patients who met the inclusion criteria of "classical PUO", of which FDG-PET/CT was performed in 31 inpatients, 15 outpatients and 11 inpatients did not have an FDG-PET/CT scan. The patient demographics, clinical characteristics and inpatient cost were analysed, together with the diagnostic performance of FDG-PET/CT and impact on clinical management. The mean age, length of stay and total cost of admission were higher for inpatients who received FDG-PET/CT versus those who did not. The median cost per patient-bed-day did not differ between the two groups. Inpatients who received earlier FDG-PET/CTs (≤ 7 days from admission) had shorter length of stays and lower total cost compared to those who received a later scan. A negative FDG-PET/CT scan, demonstrating no serious or life-threatening abnormalities resulted in subsequent discharge from hospital or outpatient clinic in 7/10 (70%) patients. There were 11/40 (28%) scans where ancillary abnormalities were identified, requiring further evaluation. FDG-PET/CT showed high diagnostic accuracy and significant impact on patient management in patients with PUO. FDG-PET/CT performed earlier in admission for PUO was associated with shorter length of stay and lower total cost.en_US
dc.subjectCost of Illnessen_US
dc.subjectFever of unknown originen_US
dc.subjectPyrexia of unknown originen_US
dc.titleFDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of Nuclear Medicine and Molecular Imagingen_US
dc.identifier.affiliationMolecular Imaging and Therapyen_US
dc.identifier.affiliationDepartment of Finance, Austin Health, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationGeneral Medicineen_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.affiliationLa Trobe University, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationLa Trobe University, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Nuclear Medicine, Royal Melbourne Hospital, 300 Grattan St, Melbourne, VIC, Australia.en_US
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone- Analytics and Reporting- Imaging and Therapy- Imaging and Therapy- Imaging and Therapy- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jul 25, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.